POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo pill aims to shrink spleens and ease symptoms in bone marrow cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 460 adults who have not taken JAK inhibitors before will receive either the combination or a …
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Massive new study aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis long-term observational study is enrolling 5,000 adults with myeloproliferative neoplasms (MPNs)—rare blood cancers like polycythemia vera and myelofibrosis. Researchers will collect health records, patient surveys, and insurance data over at least five years to track sympto…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC